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Abstract
Introduction: Aberrant RON (Recepteur d'Origine Nantais) tyrosine kinase
activation causes the epithelial cell to evade normal growth pathways, resulting in
unregulated cell proliferation, increased cell motility and decreased apoptosis.
Wildtype (wt) RON has been shown to play a role in metastasis of epithelial
malignancies. It presents an important potential therapeutic target for colorectal,
breast, gastric and pancreatic cancer. Little is known about functional differences
amongst RON isoforms RON155, RON160 and RON165. The purpose of this
study was to determine the effect of various RON kinase isoforms on cell motility.
Methods: Cell lines with stable expression of wtRON were generated by inserting
the coding region of RON in pTagRFP (tagged red fluorescence protein plasmid).
The expression constructs of RON variants (RON155, RON160 and RON165)
were generated by creating a mutagenesis-based wtRON-pTag RFP plasmid and
stably transfected into HEK 293 cells. The wound closure scratch assay was used
to investigate the effect on cell migratory capacity of wild type RON and its
variants.
Received:
2 August 2016
Accepted:
31 August 2016
Heliyon 2 (2016) e00153
http://dx.doi.org/10.1016/j.heliyon.2016.e00153
2405-8440/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Results: RON transfected cells demonstrated increased cell motility compared to
HEK293 control cells. RON165 cell motility was significantly increased compared
to RON160 (mean percentage of wound covered 37.37% vs. 32.40%; p = 0.03).
Conclusions: RON tyrosine kinase isoforms have variable cell motility. This may
reflect a difference in the behavior of malignant epithelial cells and their capacity
for metastasis.
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1. Introduction
Aberrant RON (Recepteur d' Origine Nantais) is a receptor tyrosine kinase member
of the MET proto-oncogene family with known involvement in both tumor
progression and metastasis [1, 2, 3, 4, 5, 6, 7]. In normal cells, RON is transiently
activated through binding with its ligand, macrophage-stimulating protein (MSP),
which initiates receptor autophosphorylation and upregulation of kinase activity [8,
9, 10]. However, RON is likely abnormally activated through overexpression of
receptor proteins or point mutations in the kinase domain, leading to dimerization
[11]. RON is not only directly implicated in tumorigenesis and invasiveness, but
also interacts downstream with oncogenic pathways phosphatidyl inositol-3 kinase
(PI3 K)/Akt and Ras/Raf/mitogen-activated protein kinase (MAPK) [12, 13, 14].
RON also participates in cross-talk with other oncogenic receptor tyrosine kinases
(RTKs) such as the epidermal growth factor receptor (EGFR) and Met receptor [3,
7]. Constitutive activation of the RON receptor causes the epithelial cell to evade
normal growth pathways, resulting in unregulated cell proliferation, increased cell
motility and decreased apoptosis [12, 15]. Both in vitro and in vivo experiments
have shown RON to be capable of inducing invasive phenotypes and distant tumor
metastasis [14, 16, 17].
RON receptor splice variants are increasingly implicated in mechanisms
underlying oncogenesis, metastasis and the creation of drug-resistant phenotypes
[18, 19, 20]. While generally the creation of isoforms is thought to positively
contribute to protein diversity, normal expression of splice variants can be
significantly altered in cancer [21, 22]. In fact, variants are estimated to be
abnormal in over half of cancers studied in the literature, particularly those with
high cellular proliferation such as epithelial cancers [23]. Wildtype RON is a 180-
kDa heterodimer containing 20 exons and 19 introns, composed of an extracelullar
40-kDa alpha chain and a 150-kDa transmembrane beta chain containing an
intracellular kinase [6]. Deletion or truncation of RON receptor mRNA transcripts
may result in splice variants that demonstrate constitutive autophosphorylation and
increased kinase activity [24].
At least 8 RON isoforms have been identified to date: 55 (also known as
short-form RON), 85, 110, 155, 160, 160E2/E3, and 170 [6, 15, 18, 24, 25, 26].
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Three commonly identified splice variants 155, 160 and 165 are generated by
various exon deletions in different regions of the B-chain of the RON receptor,
resulting from abnormal mRNA splicing [20]. The major known characteristics of
these isoforms are summarized in Table 1. Both RON155 and RON 160 induce
tumor formation in vivo and exhibit cell migration abilities in a ligand-independent
manner [20, 26]. RON 165, discovered in 1996 in gastric carcinoma cell line
KATO-III [24], is capable of inducing cell motility in transfected cells, though
does not demonstrate transformative or tumorigenic potential.
RON plays a role in the metastasis of epithelial malignancies and presents an
important potential therapeutic target for colorectal, ovarian, breast, gastric, lung
and pancreatic cancer [19, 27, 28, 29]. While advances in control of local disease
have been made in recent years, breast cancer remains the second leading cause of
death in women and colorectal cancer the third leading cause of cancer deaths in
both sexes in the United States [30]. The sequelae of tumor metastasis accounts for
the majority of cancer deaths. Approximately 20% of patients with colorectal
cancer are found to have distant disease at the time of diagnosis [31]. While the
development of monoclonal antibodies to wtRON is underway, little is known
about the functional differences amongst RON isoforms RON155, RON160 and
RON165, particularly differences in metastatic potential. The purpose of this study
was to determine the effect of various RON kinase isoforms on cell motility. We
hypothesized that RON isoforms will demonstrate varying cell motility.
2. Methods and materials
2.1. Cell culture
HEK 293 cells were obtained as a gift from Dr. Diane Lidke (University of New
Mexico). The cells were cultured and maintained in MEM supplemented with 10%
(v/v) fetal bovine serum at 37 °C in a humidified atmosphere of 95% air and 5%
CO2.
Table 1. Characteristics of wtRON and RON isoforms.
wtRON RONΔ155 RONΔ160 RONΔ165
Deletion/Insertion None Exon 5,6,11 Exon 5,6 Exon 11
Molecular Weight(kDa) 180 155 160 165
Structure α-chain, mature β-chain Single chain 125 kDa mature β-chain Single chain
Cellular location Membrane Cytoplasm Membrane Cytoplasm
Autophosphorylation? No Yes Yes Yes
MSP Stimulation Yes Yes Yes Yes
Article No~e00153
3 http://dx.doi.org/10.1016/j.heliyon.2016.e00153
2405-8440/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
2.2. Creation of RON and RON variant constructs
Plasmid (pDONR223-MST1R) containing the full cDNA coding region of wtRON
(Addgene, Cambridge, MA, USA) was obtained. PCR primers (forward 5′-
TCAAGCTTCGAATTCAT GGAGCTCCTCCCGCCGCTGC-3′, reverse 5′-
TCGACTGCAGAATTCTAGTGGGCCGAGGAGG-3′) were designed to amplify
the fragment from start codon to stop codon by PCR reaction (Sigma Labs, Santa
Fe, NM, USA). Amplified PCR fragments were isolated and inserted into
expression plasmid pTagRFP (red fluorescence protein). The wtRON plasmid
construct was used to generate RON isoforms RON155 (by deletion of exons 5, 6,
and 11), RON160 (by deletion of exons 5 and 6), and RON165 (by deletion of exon
11) by target deletion with InFusion HD Cloning Plus Kit (Clontech Laboratories,
Mountain View, CA, USA). All the expression plasmids were confirmed by DNA
sequencing.
2.3. Plasmid transfection and immunoblotting analysis
Plasmid constructs for wtRON, RON155, RON160 and RON165 were transfected
into HEK293 cells using Xfect Transfection Reagent (Clontech). We selected four
individual clones for each isoform. The culture medium plus 800 μg/ml of G418
was used to select the clones. The expression of wtRON and RON variant was
confirmed by immunoblotting assay using an anti-RON antibody. Endogenous
RON expression in HEK293 cells was compared with expression in five common
colon cancer cell lines to confirm the utility of employing this cell line for wtRON
and RON isoform transfection. To compare the effect of RON isoforms on
downstream signaling of the PI3 K pathway, we performed immunoblotting with
the indicated antibodies and BioRad Image LabTM software to calculate relative
quantity analysis.
2.4. Wound scratch assay
HEK293 cells, which were individually transfected with empty plasmid vector
(pTagRFP as a control) or plasmids containing wtRON, RON155, RON160 and
RON165 respectively were cultured in a 60-mm dish coated with collagen and grew
until confluence. A uniform wound was created manually in the confluent monolayer
of cells with a pipette tip. Wound closure was monitored at 0, 12 and 24 hours using a
Nikon light microscope at 10xmagnification. The percentage of wound coverage was
measured using Image-J software (Rasband, W.S., ImageJ, U. S. National Institutes
of Health, Bethesda, Maryland, USA).
2.5. Statistical analysis
All experiments were repeated independently and in triplicate. Variance in cell
motility values, if significant, was detected using first an F-test, followed by a
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Student’s T-test to compare mean values. Statistical significance was considered
for p values ≤ 0.05.
3. Results
3.1. Low to undetectable levels of endogenous RON found in
HEK293 cells
We found near undetectable endogenous RON expression in HEK cells compared
to five commonly used colon cancer cell lines (Fig. 1a). This confirmed the utility
of employing HEK293 cells for wtRON and RON isoform transfection and
subsequent motility analysis.
3.2. WtRON and RON isoforms demonstrated increased cell
motility compared to control cells
To determine differences in cell motility between RON and RON isoforms 155,
160 and 165 and control cells, a wound scratch assay was performed (Fig. 2).
Migration was monitored at 12 and 24 hours. All RON cell lines were 100%
confluent at 24 hours. Cell motility was measured by the mean change in
percentage of wound coverage at 12 hours. WtRON demonstrated the fastest
[(Fig._1)TD$FIG]
Fig. 1. (a) Endogenous expression of RON. HEK293 cells demonstrate nearly undetectable levels of
RON expression compared to five colon cancer cell lines. Please refer to Supplementary Material
Fig. 1a for full immunoblotting image. (b) Immunoblotting assay to confirm the expression of wtRON
and RON isoforms in stably transfected HEK cells. Prominent bands were confirmed for each of RON
isoforms (155, 160 and 165 kDa respectively). Please refer to Supplementary Material Fig. 1b for full
immunoblotting image.
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migration of all 5 cell lines. WtRON (36.85% +/−5.83; p < 0.002), RON 155
(34.77% +/5.27; p < 0.01) and 165 (37.37% +/− 3.66; p < 0.001) demonstrated
significantly increased motility compared to control (28.14% +/− 5.23) (Fig. 3).
RON 160 showed increased motility compared to control (mean 32.4% +/− 1.44
vs. 28.15%, +/− 1.40; p = 0.09), but did not obtain statistical significance.
[(Fig._2)TD$FIG]
Fig. 2. In vitro wound scratch assay. All lines except for pTagRFP-HEK control cells had complete
confluence by 24 hours. Wound closure at 12 hours was used to compare cell motility.
[(Fig._3)TD$FIG]
Fig. 3. Effect of RON and RON isoforms on cell motility, pTagRFP-wtRON and −RON isoforms, as
measured by the mean percent change in wound coverage at 12 hours. The error bars demonstrate the
SD of each cell line, ranging from 3.65 to 5.83.
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3.3. RON 165 demonstrated increased cell motility compared to
RON 160
The wound scratch assay analysis was also employed to compare differences between
wtRON and the three RON isoforms. RON 165 was found to have significantly
increased motility compared to RON 160 (37.37% vs. 32.40%; p = 0.03) (Fig. 2).
3.4. WtRON and RON isoforms have variable affects on PI3 K
pathway downstream signaling
Relative quantity analysis demonstrated RON160 had increased levels of Akt,
pGSK3β and FOXO3a protein expression compared to control, wtRON, RON 155
and165 (Fig. 4). WtRON and RON 160 had increased levels of GSK3β compared
to control, RON 155 and 165. PFOXO3a protein expression was increased in
RON160 and 165 compared to control, wtRON and RON 155. RON and all
isoforms were found to have decreased pAkt levels compared to control.
4. Discussion
RON tyrosine kinase is involved in tumorigenesis and metastasis in a variety of
epithelial cancers. The RON receptor interacts with the extracellular environment,
promoting cell adhesion and epithelial-mesenchymal transition, avoids apoptosis,
transforms normal cells into invasive phenotypes and activates downstream
oncogenic pathways such as PI3 K/Akt and Ras/Raf/MAPK. Various RON splice
variants also demonstrate tumorigenic and metastatic potential, though the
literature has only begun to elucidate the functional differences between them.
We have shown that HEK293 cells transfected with RON isoforms RON155,
RON160 and RON165 demonstrate variable cell motility, specifically RON 165
which exhibited increased motility compared to RON 160.
Consistent with previous literature, wtRON showed increased cell motility
compared to control cells [4, 6] and demonstrated the fastest cell migration of
[(Fig._4)TD$FIG]
Fig. 4. The effect of wt RON and RON isoforms on downstream signaling of the PI3 K pathway.
GSK3β, FOXO3a and its phosphorylated proteins were increased in RON 160 while the remaining
isoforms showed minimal variation. PAkt was decreased in wt RON and its isoforms. Please refer to
Supplementary Materials Fig. 2a–g for full immunoblotting images.
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all the cell lines studied. This is an interesting finding considering that wtRON has
ligand-dependent activation while RON isoforms are constitutively activated. We
suspect if MSP ligand was added there may be an even larger difference in cell
motility. There continues a discussion as to whether wtRON is tumorigenic or
promotes metastasis. Initial studies suggested that human wtRON was neither
tumorigenic nor metastatic [4] However, further studies [11] showed wtRON to
have transformative properties in NIH3T3 cells including long cytoplasmic
extensions and loss of contact inhibition, even in the absence of ligand stimulation.
Zhou et al. confirmed wtRON to be incapable of tumorigenesis [20]. Eyob et al.
also found knocking out RON had no effect on tumor development or growth rates,
though eliminated lung metastasis [32]. Current knowledge suggests that while
human wtRON may not have transformative properties, it is undoubtedly linked to
the ability of tumors to metastasize.
Interestingly, RON 165 exhibited the fastest migration of the three RON isoforms.
RON 165 is found in normal colorectal mucosa cells and is thought to contribute to
metastatic spread and invasive phenotypes, though not tumorigenesis [20, 24].
Conversely, RON160 is able to induce transformation, cell scattering and
tumorigenesis in athymic nude mice. RON155, first reported by Zhou et al., was
also found to induce cell scattering, transformation and tumor growth in vivo,
though less efficiently than RON160. RON160 and 155 were found to cause
multiple foci in transfected NIH3T3 cells, induce tumor formation and metastatic
spread. However, in this study the metastatic potential of RON165 was not studied
in vivo, as it was not tumorigenic in nude mice. Our study suggests that RON165
significantly increases cell motility. Overexpression of RON165 was noted in some
types of breast and colon cancer, which may explain these cancers’ extraordinary
capacity for metastasis. Further experiments in an orthotopic model are needed to
examine the true functional differences in metastatic potential of wtRON and RON
isoforms, particularly RON165.
Understanding the ability of tumors to metastasize is of utmost clinical importance.
The invasion of metastatic disease to distant organs is the main cause of death in
most cancer patients [33]. A hallmark of colorectal cancer is the ability to invade
adjacent organs and metastasize to remote locations such as the liver or lung [34].
In normal colon epithelial cells, RON is barely expressed, though is highly
expressed and constitutively activated in many colorectal cancer cell lines [33].
However, treatment of colorectal cancer is difficult as a significant degree of
genetic heterogeneity leads to highly variable phenotypes [35]. The existence of
splice variation adds yet another level of complexity to an individual patient’s
tumor. RON isoforms are related to deregulation of mRNA splicing machinery and
not genetic mutations [15]. Research into splicing factors is currently developing,
specifically examining the functions of a silencer and enhancer on exon 12 that
may regulate aberrant splicing in epithelial cancers [18] or studying the SRSF2
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gene which promotes inclusion of exon 11 [36, 37]. In addition, clarifying the
functional differences between isoforms important as RON variants display
differing cellular locations, with RON160 being entirely intracellular, while RON
155 and 165 span the cellular membrane. As RON and other RTKs represent a
developing target for monoclonal antibodies [38, 39] RON isoforms may require a
different therapeutic approach.
In addition to comparing cell motility, we performed a preliminary analysis of
wtRON and RON isoform effects on downstream signaling in the PI3 K pathway.
Most of the current literature regarding PI3 K/Akt pathways in cancer cells
supports the hypothesis that increased cell motility would correlate with increased
downstream protein expression, signifying activation of RON and PI3 K pathways.
We were surprised to find that RON 160 increased the expression of several
proteins compared to wtRON, RON 155 and 165 and that pAkt was decreased in
all cell lines compared to control. Recent literature has revealed that protein
signaling in the PI3 K/Akt signally pathway is anything but linear, with evidence
that in some cases PI3 K and Akt may operate independently of each other in
cancer cells [40]. Our preliminary data shows that there may be variation in
downstream protein expression, though the clinical significance of these findings
are not yet clear. Further study is needed to explore the effects of RON and its
splice variants on the downstream pathways such as PI3 K/Akt and Ras/Raf/
MAPK.
This study includes a few notable limitations. The three RON isoforms studied
demonstrated increased cell motility compared to control cells as expected. In our
study, RON 160 was increased compared to control, though did not reach statistical
significance, which we attribute to a smaller sample size of available images. Our
plasmid constructs were transfected into normal epithelial cells as opposed to a
colon cancer cell lines. This is because many colon cancer cell lines have wtRON
and RON splice variant expression [15, 33]. This HEK293 cell model, having near
undetectable levels of endogenous RON expression, allows for preliminary
analysis of the impact of isolated splice variants on cell motility. Thus, we cannot
yet comment on RON isoforms cell motility in tumor cells or how the differences
in cell motility will translate in an in vivo animal model.
In this study we demonstrate that RON tyrosine kinase splice variants demonstrate
variable cell motility in normal cells. Variation in cell motility between RON
isoforms may represent a difference in metastatic potential. Future studies aimed at
exploring the functional differences of RON isoforms in in vivo pre-clinical models
will help to determine their role as potential therapeutic targets in both localized
cancers and metastatic disease.
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